# Venetoclax and Lintuzumab-Ac225 in AML Patients

> **NCT03867682** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Actinium Pharmaceuticals** · enrollment: 38 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Relapsed Adult AML

## Interventions

- **BIOLOGICAL:** Lintuzumab-Ac225
- **DRUG:** Venetoclax
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT03867682
- **Lead sponsor:** Actinium Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-15
- **Primary completion:** 2023-11
- **Final completion:** 2024-06
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867682, "Venetoclax and Lintuzumab-Ac225 in AML Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03867682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*